ArticleMucosal immunology2012
Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab.
Article in Mucosal immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 121 citations in OpenAlex.
- Positive rate of wheat allergens in the Chinese allergic population: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Oral immunotherapy for milk allergy.The Cochrane database of systematic reviews · 2012Pooled it
- Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy.The Journal of allergy and clinical immunology · 2017Trial
- Omalizumab facilitates rapid oral desensitization for peanut allergy.The Journal of allergy and clinical immunology · 2017Trial
- Modulation of dendritic cell innate and adaptive immune functions by oral and sublingual immunotherapy.Clinical immunology (Orlando, Fla.) · 2014Trial
- A pilot study of omalizumab to facilitate rapid oral desensitization in high-risk peanut-allergic patients.The Journal of allergy and clinical immunology · 2013Trial
- Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.International archives of allergy and immunology · 2013Trial
- GAClinical and translational allergy · 2024Review
- Allergen-specific IgA and IgG antibodies as inhibitors of mast cell function in food allergy.Frontiers in allergy · 2024Review
- IgG:FcγRIIb signals block effector programs of IgE:FcεRI-activated mast cells but spare survival pathways.The Journal of allergy and clinical immunology · 2023Article
- Combining Anti-IgE Monoclonal Antibodies and Oral Immunotherapy for the Treatment of Food Allergy.Clinical reviews in allergy & immunology · 2022Review
- AIT: New Avenues in Allergen Immunotherapy.Handbook of experimental pharmacology · 2022Article
- Oral Immunotherapy for Children with Cow's Milk Allergy.Pathogens (Basel, Switzerland) · 2021Review
- Immune changes beyond Th2 pathways during rapid multifood immunotherapy enabled with omalizumab.Allergy · 2021Article
- Review
- Use of biologics in allergen immunotherapy.Allergologie select · 2021Review
- Role of orally induced regulatory T cells in immunotherapy and tolerance.Cellular immunology · 2021Review
- B cells and the microbiota: a missing connection in food allergy.Mucosal immunology · 2021Review
- Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma.Allergy · 2020Review
- Three Candidate Probiotic Strains Impact Gut Microbiota and Induce Anergy in Mice with Cow's Milk Allergy.Applied and environmental microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Food allergy is a major public health problem, for which there is no effective treatment. We examined the immunological changes that occurred in a group of children with significant cow's milk allergy undergoing a novel and rapid high-dose oral desensitization protocol enabled by treatment with omalizumab (anti-immunoglobulin (Ig)E monoclonal antibodies). Within a week of treatment, the CD4(+) T-cell response to milk was nearly eliminated, suggesting anergy in, or deletion of, milk-specific CD4(+) T cells. Over the following 3 months while the subjects remained on high doses of daily oral milk, the CD4(+) T-cell response returned, characterized by a shift from interleukin-4 to interferon-γ production. Desensitization was also associated with reduction in milk-specific IgE and a 15-fold increase in milk-specific IgG4. These studies suggest that high-dose oral allergen desensitization may be associated with deletion of allergen-specific T cells, without the apparent development of allergen-specific Foxp3(+) regulatory T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.